Last edition
News about "BioArctic "
China Adds Leqembi to Innovative Drug Insurance List
BioArctic’s partner Eisai said Leqembi has been added to China’s new Commercial Insurance Innovative Drug List, a move by the NHSA that broadens access to the Alzheimer’s therapy for patients in the early stages of the disease.
BioArctic | 09/12/2025 | By Akanki | 148
Health Canada Grants Authorisation for Leqembi (Lecanemab)
BioArctic has the right to commercialise Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialisation in the region.
BioArctic | 28/10/2025 | By Dineshwori | 160
This marks the third collaboration BioArctic has entered into with partners using the BrainTransporter technology.
BioArctic | 27/08/2025 | By Dineshwori | 302
Novartis Expands Collaboration with BioArctic, Eyes Licensing Opportunity Worth Up to $772 Million
The partnership focuses on combining BioArctic’s BrainTransporter technology with a Novartis proprietary antibody to develop a novel drug candidate. Should Novartis proceed, it would take full responsibility for the candidate’s global development and commercialization.
BioArctic | 26/08/2025 | By Darshana | 307
Leqembi sBLA for Alzheimers IV Maintenance Moves Forward with FDA
Eisai has submitted a supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb intravenous (IV) maintenance dosing to the US Food and Drug Administration (FDA).
BioArctic | 01/04/2024 | By Manvi | 620
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy